Scienture (NASDAQ:SCNX) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Scienture (NASDAQ:SCNX) from a hold rating to a sell rating in a report issued on Sunday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scienture in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Scienture Price Performance

SCNX opened at $0.50 on Friday. Scienture has a 1 year low of $0.46 and a 1 year high of $4.13. The company has a market capitalization of $20.32 million, a price-to-earnings ratio of -0.50 and a beta of 3.00. The firm’s fifty day moving average price is $0.55 and its two-hundred day moving average price is $0.96.

Scienture (NASDAQ:SCNX) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.19) earnings per share for the quarter. The company had revenue of $0.59 million for the quarter.

Scienture Company Profile

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.